Aurobindo Pharma unveils its growth prospectus

Aurobindo Pharma, a seventh largest generic company by volume in the US markets, has filed 2,428 and 421 formulations in Europe and US respectively with different regulatory authorities in last six months. The pharma-major also has increased filing for sustainable future growth. It has also cut down net debt to equity from 1.2x in FY13 to 0.4x in H1FY17.

Aurobindo Pharma has lined up more than 20 products in the segment of Oncology and Hormones. These product launches and their commercialisation is to start from April 2019. The company will launch commercially 'Bx' of pneumococcal conjugate vaccine with an addressable market size of USD 6 billion in 2019.

Aurobindo Pharma’s four products from Microspehers which are under development will be filed soon and start commercialization. The company to start development work for four inhaler products also. Meanwhile, first set of product launch and its commercialization has already started.

The company has started biosimilars manufacturing facility and will file biosimilars globally. Aurobindo Pharma plans its commercialisation from FY20. The company also has plans for filing 1-2 505b2 NDAs per year, according to its communique.